Literature DB >> 8786498

Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid.

J R Hocker1, K L Saving.   

Abstract

Hemorrhagic complications are common in patients placed on extracorporeal life support (ECLS), especially in those who have additional risk factors. Several centers use epsilon-aminocaproic acid (EACA) in their high-risk ECLS patients in an attempt to decrease the incidence of such complications, despite the fact that no controlled trials have been performed examining the risks and benefits of its use. The authors report the case of a neonate who had fatal aortic thrombosis during EACA administration. Also included is a discussion of the use of EACA in patients who require cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8786498     DOI: 10.1016/0022-3468(95)90416-6

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

1.  Temporally and regionally disparate differences in plasmin activity by tranexamic acid.

Authors:  Daryl L Reust; Scott T Reeves; James H Abernathy; Jennifer A Dixon; William F Gaillard; Rupak Mukherjee; Christine N Koval; Robert E Stroud; Francis G Spinale
Journal:  Anesth Analg       Date:  2010-03-01       Impact factor: 5.108

2.  Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice.

Authors:  Bihui Huang; Arun B Deora; Kai-Li He; Kang Chen; Guangzhi Sui; Andrew T Jacovina; Dena Almeida; Peng Hong; Paul Burgman; Katherine A Hajjar
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

3.  Interstitial plasmin activity with epsilon aminocaproic acid: temporal and regional heterogeneity.

Authors:  Daryl L Reust; Scott T Reeves; James H Abernathy; Jennifer A Dixon; William F Gaillard; Rupak Mukherjee; Christine N Koval; Robert E Stroud; Francis G Spinale
Journal:  Ann Thorac Surg       Date:  2010-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.